SCHEMBL30442170

SCHEMBL30442170

Cc1ccc(F)cc1-c1cc(C)n(C2CC3(CNC3)C2)n1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 4/20 0.36
CDK9 P50750 4/20 0.36
NISCH Q9Y2I1 1/20 0.36
CDK1 P06493 1/20 0.35
CDK4 P11802 1/20 0.35
CCNA2 P20248 1/20 0.35
CCND1 P24385 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
CDK7 P50613 1/20 0.35
CCNH P51946 1/20 0.35
CCNA1 P78396 1/20 0.35
CDK3 Q00526 1/20 0.35
ABL1 P00519 10/20 0.34
LRRK2 Q5S007 1/20 0.32
MAP3K12 Q12852 2/20 0.32
EPHA4 P54764 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25432745 0.87 MAP3K12 (0.41) CCNT1CDK9NISCHCDK1CDK4
SCHEMBL25434333 0.81 CCNT1 (0.38) CCNT1CDK9NISCHABL1
SCHEMBL30442142 0.81 CCNT1 (0.38) CCNT1CDK9NISCHABL1
SCHEMBL30441927 0.81 GAA (0.36) MAP3K12
SCHEMBL25431401 0.80 CCNT1 (0.36) CCNT1CDK9NISCHCDK1CDK4
SCHEMBL25263665 0.75 CCNT1 (0.37) CCNT1CDK9NISCHABL1
SCHEMBL25292323 0.71 MET (0.36) CCNT1CDK9NISCH
SCHEMBL30442150 0.69 CCNT1 (0.36) CCNT1CDK9
SCHEMBL25430783 0.69 CCNT1 (0.36) CCNT1CDK9
Trifluoroacetic Acid SCHEMBL30442592 0.69 PDE9A (0.35) CCNT1CDK9ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214974-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) PSY THERAPEUTICS, INC. (US) 2025-07-03 US disclosed
US-12286421-B2 Inhibiting monoacylglycerol lipase (MAGL) PSY THERAPEUTICS, INC. (US) 2025-04-29 US disclosed
US-20250084065-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) PSY THERAPEUTICS, INC. (US) 2025-03-13 US disclosed
EP-4457213-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) Psy Therapeutics, Inc. (US) 2024-11-06 EP disclosed
US-20240308985-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) PSY THERAPEUTICS, INC. (US) 2024-09-19 US disclosed
CN-118574807-A Inhibition of monoacylglycerol lipase (MAGL) PSY治疗公司 2024-08-30 CN disclosed
WO-2023130023-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) PSY THERAPEUTICS, INC. (US) 2023-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214974-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) MGLL, PNLIP, LIPC CCNT1 4448/4885CDK9 2512/4885NISCH 2407/4885
US-20250084065-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) MGLL, PNLIP, LPL CCNT1 4757/4885CDK9 3352/4885NISCH 2597/4885
US-12286421-B2 Inhibiting monoacylglycerol lipase (MAGL) MGLL, PNLIP, LIPC CCNT1 4448/4885CDK9 2512/4885NISCH 2407/4885
US-20240308985-A1 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) MGLL, PNLIP, LIPC CCNT1 4448/4885CDK9 2512/4885NISCH 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.